<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04857866</url>
  </required_header>
  <id_info>
    <org_study_id>XmAb27564-01</org_study_id>
    <nct_id>NCT04857866</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study of the Safety, Tolerability, and Pharmacokinetics of XmAb®27564 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xencor, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Xencor, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending-dose study&#xD;
      of subcutaneously administered XmAb27564 or placebo in healthy male and female subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will determine the safety and tolerability, pharmacokinetics, and pharmacodynamics&#xD;
      of single ascending doses of XmAb27564 in normal healthy volunteers. XmAb27564 is an&#xD;
      engineered IL-2 mutein being developed for autoimmune diseases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 19, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events, graded by CTCAE Version 5.0</measure>
    <time_frame>Up to Day 30</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Drug Concentration - Time Curve from Zero to the End of Observation</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Maximum Observed Drug Concentration (Cmax) of XmAb27564 after a single dose</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Measurement of Cmax</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Time to Maximum Plasma Concentration (Tmax) of XmAb27564 after a single dose</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Measurement of Tmax</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Time to Decrease in Concentration by Half (T1/2) of XmAb27564 after a single dose, due to elimination</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Measurement of T1/2</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD: Measurement of Change in Number of Regulatory T Cells</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD: Measurement of Change in Number of Subsets of Conventional T Cells in Blood</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD: Measurement of Change in Number of Natural Killer Cells (NK Cells) in Blood</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD: Measurement of Cytokines in Blood</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Safety in Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Single Ascending Dose - XmAb27564 Subcutaneous injection of Dose A, B or C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Dose - Placebo Subcutaneous injection of placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XmAb27564</intervention_name>
    <description>Single ascending dose of XmAb27564</description>
    <arm_group_label>Single Ascending Dose - XmAb27564 Subcutaneous injection of Dose A, B or C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose of placebo</description>
    <arm_group_label>Single Ascending Dose - Placebo Subcutaneous injection of placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Total body weight 50.0 to 100.0 kg and body mass index (BMI) 19.0 to 35.0 kg/m2&#xD;
&#xD;
          -  In good general health with no clinically significant abnormality identified on&#xD;
             medical or laboratory evaluation and no history of any clinically significant&#xD;
             disorder, condition, or disease.&#xD;
&#xD;
          -  A nonsmoker for at least 12 weeks preceding screening&#xD;
&#xD;
          -  Female subjects of childbearing potential must agree to use a highly effective method&#xD;
             of birth control during and for 30 days after administration of investigational&#xD;
             product (IP).&#xD;
&#xD;
          -  Fertile male subjects must be willing to practice a highly effective method of birth&#xD;
             control during and for 30 days after administration of IP and agree not to donate&#xD;
             sperm from screening through 30 days after administration of IP.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have a clinically relevant history or presence of diseases or disorders&#xD;
             that would pose a significant risk to subject's safety or significantly interfere with&#xD;
             the study evaluation, procedures, or completion&#xD;
&#xD;
          -  Subjects with history of any cardiovascular event&#xD;
&#xD;
          -  Subjects with vital sign values outside the normal ranges&#xD;
&#xD;
          -  Subjects who are positive for MTB QuantiFERON, hepatitis B surface antigen, hepatitis&#xD;
             C virus antibody, severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) by&#xD;
             polymerase chain reaction (PCR)/antigen, or human immunodeficiency virus Type I or&#xD;
             Type II tests at screening&#xD;
&#xD;
          -  Subjects with signs or symptoms consistent with active viral infection&#xD;
&#xD;
          -  Subjects with baseline eosinophil elevation or a history of urticaria, asthma,&#xD;
             allergic dermatitis, food allergy or eosinophilic esophagitis&#xD;
&#xD;
          -  Subjects who have evidence of any bacterial, viral, parasitic, or systemic fungal&#xD;
             infections requiring treatment within the 21 days prior to randomization; or&#xD;
             hospitalization due to infection within 3 months prior to randomization&#xD;
&#xD;
          -  Subjects who have had any prior investigational treatment with interleukin 2 (IL-2)&#xD;
             therapies or have received any investigational agent within five half-lives of the&#xD;
             study drug&#xD;
&#xD;
          -  Subjects with a known or suspected sensitivity to products from mammalian cell lines&#xD;
&#xD;
          -  Subjects who have received live vaccines ≤ 2 months prior to screening or any vaccine&#xD;
             within the past 14 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Hickingbottom, MD</last_name>
    <role>Study Director</role>
    <affiliation>Vice President, Clinical Development, Xencor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ralph Zitnik, MD</last_name>
    <phone>650-996-5321</phone>
    <email>rzitnik@xencor.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Seven Lueder-Powers</last_name>
    <phone>858-769-6357</phone>
    <email>slueder-powers@xencor.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ICON Early Phase Services, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cassandra Key, MD</last_name>
      <phone>210-283-4500</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 14, 2021</study_first_submitted>
  <study_first_submitted_qc>April 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

